European Psychiatry
June 1, 2026
E. D. Cindik-Herbrueggen, A. S. Kucukali
Introduction Adult attention-deficit/hyperactivity disorder (ADHD) frequently co-occurs with mood and anxiety disorders (Sandstrom et al. Acta Psychiatr Scand 2021;143 380–391), and when major depressive disorder (MDD) is present, it often follows a treatment-resistant course (Thapar et al. J Child Psychol Psychiatry 2023;64 4–15). Intranasal esketamine, a non-competitive NMDA-receptor...
European Psychiatry
June 1, 2026
I. C. Mândraș, A. L. Comșa
Introduction Suicidality represents a major clinical and public health challenge, particularly among patients with treatment-resistant depression (TRD), who carry a disproportionately high risk of suicide. Traditional antidepressants often have delayed onset and limited efficacy in reducing suicidal ideation in this high-risk population, highlighting the need for rapid-acting interventions....
The Brown University Psychopharmacology Update
June 1, 2026
A two‐year extension of a trial of esketamine nasal spray in patients with treatment‐resistant depression has found no new safety concerns associated with long‐term use of the drug. The overall relapse rate across both the original trial and the extension was 6.9%.
European Psychiatry
June 1, 2026
Introduction Treatment-resistant depression (TRD) represents a major challenge in psychiatry. Nearly one-third of patients with major depressive disorder fail to achieve remission despite adequate antidepressant therapy, and about 30% attempt suicide during their lifetime. Given this elevated risk, identifying treatments that rapidly reduce depressive symptoms and suicidality while improving...
International journal of psychiatry in clinical practice
June 1, 2026
Damian Swieczkowski, Aleksander Kwaśny, Michal Pruc et al.
To explore sex, racial and ethnic disparities in esketamine clinical trials for mental health disorders registered on ClinicalTrials.gov. We conducted a registry-based cross-sectional analysis of interventional esketamine trials with results posted on ClinicalTrials.gov (cut-off date: 10 February 2025). Using predefined eligibility criteria, two investigators independently extracted and...
European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology
June 1, 2026
Andreas Reif, Yağcıoğlu Ae Anıl, Istvan Bitter et al.
3 citations
Optimising patient outcomes in treatment resistant depression (TRD) requires treatments which provide sustained remission, without relapse, and tolerability in the long term. ESCAPE-LTE (NCT04829318) was a phase IV, single-arm, 2-year (104 weeks) long-term extension of ESCAPE-TRD (NCT04338321; 32 weeks), a rater-blinded, randomised, active-controlled trial, which evaluated the safety,...
Journal of Psychiatric Research
June 1, 2026
Ludovic Samalin, Maud Rothärmel, Lila Mekaoui et al.
In patients with treatment-resistant depression (TRD), the efficacy and tolerance of intranasal esketamine (ESK) spray, alone or combined with oral antidepressants, has been supported by clinical trials and observational studies. The French real-world ESKALE study assessed the benefit of ESK in 157 patients with TRD. In this post-hoc analysis of the ESKALE study we aimed to describe the...
Asian Journal of Psychiatry
June 1, 2026
Fabiola Raffone, Filippo Mazzoni, Arianna De Ciechi et al.
3 citations
Suicidal ideation and deliberate self-harm are frequent and persistent in treatment-resistant depression (TRD), particularly when comorbid borderline personality disorder (BPD) is present. Real-world evidence on antisuicidal outcomes during intranasal esketamine in this population remains limited. In this multicentre prospective observational study, 90 outpatients with TRD received intranasal...
medRxiv Preprint Server
May 31, 2026
Yves Martins Varela, Patrícia Cavalcanti-Ribeiro, Geovan Menezes de Sousa et al.
preprint
Background Ketamine has emerged as an effective rapid-acting treatment for treatment-resistant depression (TRD), producing significant antidepressant effects within hours of administration. Given ketamine’s capacity to induce states of heightened neuroplasticity and psychological openness, psychotherapy may represent a meaningful complement to its pharmacological effects — facilitating...
Ther Adv Psychopharmacol
May 22, 2026
Liliana Patarroyo-Rodriguez, Vanessa K. Pazdernik, Jennifer L. Vande Voort et al.
Background: Ketamine and esketamine ((es)ketamine) rapidly reduce depressive symptoms and suicidal ideation (SI) in treatment-resistant depression (TRD), but whether early SI improvement during the acute phase of the treatment predicts reduced suicide-associated emergency department (SAED) visits over the longer term remains unclear. Objectives: To examine whether early improvements in SI,...